antibody cocktail‘ therapy at
Fortis Hospital in Mohali near Chandigarh on Sunday, days after the treatment was given to two similar patients in Delhi and Gurgaon hospitals.
The Mohali-based Fortis Hospital, in a statement, said the patient, who had tested positive for the infection two days ago, is a diabetic with chronic kidney disease.
“He was administered one dose of the cocktail intravenously,” the statement said, adding the patient is stable after the infusion.
Dr Zafar Ahmed, a senior consultant with the Critical Care, Pulmonology and Chest and Sleep Medicine Department of the Mohali Fortis Hospital, said like antibodies, which are proteins generated by the body to fight disease, monoclonal antibodies are ‘artificially created in the lab’.
“In this cocktail, Casirivimab and Imdevimab are monoclonal antibodies that specifically block the spike protein of SARS-CoV-2, thereby preventing the coronavirus attachment and entry into human cells,” said Dr Ahmed in the statement.
“This is another very important step that has been taken by the medical community to effectively combat the pandemic and help people recover faster,” he added.
Drug majors Roche India and
had on Monday announced the launch of Roche’s Antibody Cocktail in India, priced at Rs 59,750 per dose for the treatment of mild to moderate COVID-19 patients facing high risks.
“The first batch of the Antibody Cocktail (Casirivimab and Imdevimab) is now available in India while a second batch will be made available by mid-June. In total, they can potentially benefit 2,00,000 patients as each of the 1,00,000 packs that will be available in India offers treatment for two patients,” Cipla and Roche had said in a joint statement.
Cipla will distribute the product by leveraging its strong distribution strengths across the country, it added.
As per the statement, the drug will be available through leading hospitals and Covid treatment centres.
The Central Drugs Standards Control Organisation (CDSCO) had recently provided an emergency use authorisation (EUA) for the Antibody Cocktail in India. It has also received a EUA in the US and several EU countries.
The antibody cocktail is to be administered for the treatment of mild to moderate COVID-19 in adults and paediatric patients (12 years of age or older, weighing at least 40 kg) who are confirmed to be infected with SARS-COV2 and who are at high risk of developing severe COVID-19 disease and do not require oxygen.